Ask AI
Therapies for Cancer Cachexia

CE / CME

Current, Novel and Emerging Therapies on the Horizon for Cancer Cachexia

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

European Learners: 0.25 EBAC® CE Credit

Released: March 24, 2026

Expiration: September 23, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Jeffrey Crawford, MD, reviews current pharmacologic guidelines and the rationale and available evidence supporting the investigation of new and emerging therapeutic strategies for the optimal management of patients with advanced cancer and cachexia. These topics were presented by Dr Crawford during a previously held live virtual webinar, titled: Global Expert Think Tank: Hope on the Horizon? Key Evidence and Real-world Insights to Optimize the Diagnosis and Treatment of Cancer Cachexia.

Please note that the key points discussed in this module are illustrated with thumbnails from an accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Decera Clinical Education plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with cancer do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

In patients with advanced cancer and significant weight loss, how is ponsegromab thought to contribute to a multimodal cancer cachexia management plan?